The November midterm elections, potential litigation challenging the Paramount-Warner Bros. Discovery merger, and President Donald Trump’s ongoing bids to fire Federal Reserve Governors Jerome Powell and Lisa Cook are among key catalysts Bloomberg Intelligence policy and litigation analysts will be watching in 2H. In this episode of Votes and Verdicts, we also discuss crypto legislation to bring clarity for companies like Coinbase, deregulation to ease capital rules for banks such as JPMorgan and Bank of America, relaxed TV-ownership caps for companies like Nexstar and Sinclair and rulemaking and litigation concerning prediction markets like Kalshi. Further, we explore antitrust cases against Live Nation and Google, BNP Paribas’ Sudan genocide appeal, and class actions against Bayer and Reckitt’s Mead Johnson.

See omnystudio.com/listener for privacy information.

What is the Trump administration’s approach to Cuba? How does it differ from President Donald Trump’s first term? And what happens next in the short term and the longer term? Ricardo Herrero, executive director of the Cuba Study Group, joins Bloomberg Intelligence’s Elliott Stein and Nathan Dean on this episode of the Votes and Verdicts podcast to discuss these and other related questions. Herrero also discusses the risks and opportunities for companies operating or seeking to operate in Cuba, and explores implications for banks like Santander and BBVA, for hotels like Melia and Iberostar and for crypto companies like Coinbase, among other sectors.

See omnystudio.com/listener for privacy information.

Bayer, facing tens of thousands of lawsuits over weedkiller Roundup, has set its sights on the Supreme Court. Dale Mullen, partner and co-chair of the business and corporate law section at Whiteford, joins Bloomberg Intelligence litigation analyst Holly Froum on this episode of the Votes and Verdicts podcast to discuss Bayer Monsanto’s appeal to the US Supreme Court of a $1.25 million verdict holding it liable for failing to warn that Roundup causes cancer. They discuss Bayer’s arguments, the company’s chance of success on appeal, risks that remain even if it secures a Supreme Court victory and more.

See omnystudio.com/listener for privacy information.